Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.
Back to dashboard
Company Information
About this company
Key people
Jonas Ekblom
Independent Chairman of the Board
Nikolaj Sorensen
Independent Director
Anna Ljung
Chief Financial Officer
Helena Maria Jansson
Chief Business Officer, Deputy Chief Executive Officer
Mark Beveridge
Vice President Finance
Annica Magnusson
Senior Director Regulatory Affairs
Vaidrius Navikas
Chief Medical Officer
Richard Ding
Independent Director
Isabelle Ducellier
Independent Director
Otto Skolling
Independent Director
Click to see more
Key facts
- Shares in issue49.30m
- EPICMOB
- ISINSE0020353928
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capSEK 567.00m
- Employees5
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.